The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 73 of the 107 sources its claims cite were checked for support.
Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs
Open accessAbstract
PURPOSE OF REVIEW: To summarize the developing evidence on novel 2-benzlbenzimidazole opioids (nitazene analogs), including pharmacology, potency, toxicology, management of overdose, and public health issues that are caused by this set of compounds as there is an increasing presence in illicit drug markets. RECENT FINDINGS: Nitazene analogs include those such as isotonitazene, metonitazene, protonitazene, and etonitazene are highly potent mu opioid receptor agonists and are increasingly detected in counterfeit and illicit pharmaceutical products with exposure in other substances including other drugs. Reports from multiple clinical, forensic, and public health investigations have all demonstrated that severe opioid toxicity can be characterized by profound respiratory depression, which is seen in nitazene compounds. Detection remains a central issue with this compound because these derivatives frequently are missed in routine toxicology screening. Nitazene analogs represent a new class of synthetic opioids that are associated with a high overdose risk related to high potency and increased prevalence worldwide. New techniques for overdose reversal include improvements in the pharmacology of opioid antagonists, prolonged and improved monitoring, and advances in life support inside and outside the hospital setting.
Overview
CoChat Summary
TL;DR
This narrative review summarizes the pharmacology, potency, toxicology, detection, and public health impact of 2-benzylbenzimidazole opioids ("nitazenes"), a class of highly potent mu-opioid receptor agonists increasingly found in illicit and counterfeit drug supplies. It emphasizes that routine immunoassay screening frequently misses these compounds, that naloxone remains first-line reversal but may require repeat dosing, and that surveillance and harm-reduction efforts lag behind the market.
Key findings
- Nitazene analogs are potent mu-opioid receptor agonists; the review's adapted potency table (relative to heroin = 1) lists fentanyl 50, metonitazene 50, protonitazene 100, isotonitazene 250, and etonitazene 500. Etonitazene is separately described as "1000-fold more potent than morphine."
- In a case series of laboratory-confirmed nitazene poisoning, naloxone successfully reversed toxicity, but repeat naloxone administration was required in approximately 45% of patients receiving naloxone. Experimental data suggest nitazenes dissociate slowly from the mu-opioid receptor and are more resistant to naloxone antagonism than rapidly dissociating opioids.
- Routine hospital immunoassay panels frequently miss nitazenes due to minimal cross-reactivity with antibodies for morphine, heroin, and fentanyl; definitive identification relies on LC-MS/MS, LC-QTOF-MS, or LC-HRMS. Nitazene test strips detected 28 of 36 nitazene compounds, with false negatives and false positives linked to high caffeine concentrations.
- Nearly 7,000 nitazene submissions were reported in the U.S. National Forensic Laboratory Information System (NFLIS) between 2019 and 2025; nitazene analogs have also been detected in wastewater samples across multiple countries, and overdoses are reported in the UK, Norway, Australia, and the United States.
Methods
- Narrative review (no stated systematic search strategy, inclusion criteria, or PRISMA-type methodology) covering pharmacology, potency, clinical toxicology, overdose management, and public health challenges of nitazene analogs.
- Evidence base is a synthesis of cited in vitro receptor pharmacology, in vivo animal studies, human metabolism studies, clinical case reports and case series, forensic/toxicology surveillance data, and wastewater epidemiology.
- Potency comparisons are presented in a single adapted table (Table 1) drawing on two cited sources; the text notes potency estimates vary by experimental endpoint (binding affinity, signaling assays, antinociception, behavioral models) and should be treated as approximations.
Limitations
- Stated in the paper: potency rankings "should be interpreted as approximations rather than absolute values" because estimates vary by experimental endpoint; the review also notes that additional evidence is needed before a longer-acting antagonist such as nalmefene can be recommended to replace naloxone.
- Evident from the text: as a narrative review without a described search strategy or systematic selection criteria, it is susceptible to selection and reporting bias, and much of the clinical evidence rests on case reports and case series rather than controlled studies.
- Evident from the text: several key claims (e.g., greater naloxone requirements than fentanyl overdose, prolonged receptor occupancy) are attributed to single studies or small series, and the review does not quantify prevalence trends beyond the NFLIS submission count.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
57 Valid · 8 Not valid · 20 Not checked · 11 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Isotonitazene is an extremely effective nitazene analog with potency at the mu opioid receptor that exceeds that of fentanyl in terms of agonism [21].”
§ Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs > Pharmacology > Isotonitazene
What the sources say
- Could not verifycites [21] Vandeputte MM, Stove CP. Navigating nitazenes: A pharmacological and toxicological overview of new synthetic opioids with a 2-benzylbenzimidazole core. Neuropharmacology. 2025;275:110470. https://doi.org/10.1016/j.neuropharm.2025.110470. sourceExperimental — accuracy not yet measured
The indexed passages are from a repository listing, not the paper’s full text. Its abstract says several nitazene analogues are more potent than fentanyl at activating the mu-opioid receptor, but does not identify isotonitazene as one of them. Searches for isotonitazene’s potency relative to fentanyl returned no decisive passage from the paper’s body. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“From a clinical standpoint, isotonitazene’s high receptor potency and potential for active metabolites help explain why intoxications present with profound central nervous system depression, miosis, and respiratory depression even when the exposure history may be unclear [6].”
§ Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs > Pharmacology > Isotonitazene
What the sources say
- Partly supportedcites [6] Kozell LB, Eshleman AJ, Wolfrum KM, Swanson TL, Bloom SH, Benware S, et al. Pharmacologic Characterization of Substituted Nitazenes at µ, κ, and ∆ Opioid Receptors Suggests High Potential for Toxicity. J Pharmacol Exp Ther. 2024;389(2):219–28. https://doi.org/10.1124/jpet.123.002052. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies N-desethyl isotonitazene as an isotonitazene metabolite with similar μ-opioid receptor affinity and higher potency, and reports respiratory depression associated with it. The Introduction describes respiratory distress, confusion, and possible coma as signs of nitazene toxicity. The copy does not establish miosis or an unclear exposure history as features of isotonitazene intoxication. (LLM, conf=0.88)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“It has been described as 1000-fold more potent than morphine is at the same receptor [23].”
§ Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs > Pharmacology > Etonitazene
What the sources say
- Supportedcites [23] Pereira JRP, Quintas A, Neng NR, Nitazenes. The Emergence of a Potent Synthetic Opioid Threat. Molecules. 2025;30(19):3890. https://doi.org/10.3390/molecules30193890. source
The Introduction describes etonitazene as 1000-fold more potent than morphine. Section 3 identifies the μ-opioid receptor as the site of nitazenes’ action and compares their receptor binding with morphine. The supplied passages do not include page numbers. (LLM, conf=0.93)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although nitazenes are often discussed as a class, minimal structural differences at the benzimidazole core, the N, N- dialkylaminoethyl side chain, as well as the para-substituted benzyl ring can profoundly alter receptor binding, potency, metabolism, and expected toxicity [17].”
§ Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs > Pharmacology
What the sources say
- Partly supportedcites [17] Vandeputte MM, Glatfelter GC, Walther D, Layle NK, St Germaine DM, Ujváry I, et al. Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro µ-opioid receptor assays and in vivo behavioral studies in mice. Pharmacol Res. 2024;210:107503. https://doi.org/10.1016/j.phrs.2024.107503. sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) report that changes to the benzimidazole substituent, amino side chain, and benzylbenzimidazole linker alter opioid activity; the Results report differences in µ-opioid receptor affinity and potency. The paper does not establish that these structural changes alter metabolism, and the Discussion says that specific adverse effects such as respiratory depression were beyond the study’s scope. It suggests overdose risk from high receptor potency and efficacy rather than measuring changes in toxicity. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In vivo studies of etonitazene and related analogs demonstrate classic opioid-like pharmacodynamic effects, including antinociception, altered locomotor activity, and reduced body temperature in animal models [17].”
§ Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs > Pharmacology > Etonitazene
What the sources say
- Supportedcites [17] Vandeputte MM, Glatfelter GC, Walther D, Layle NK, St Germaine DM, Ujváry I, et al. Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro µ-opioid receptor assays and in vivo behavioral studies in mice. Pharmacol Res. 2024;210:107503. https://doi.org/10.1016/j.phrs.2024.107503. source
The Results (page not provided) report antinociception, changes in locomotor activity, and decreased body temperature after testing etonitazene and selected analogues in mice. The Discussion describes the analogues’ effects as opioid-like. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
49 more claims · 33 with their cited sources checked
Create a free account to see all 96 claims and to verify the 2 references still open.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 1
Citations
Cites
A brief history of the opioid epidemic and strategies for pain medicine
Jones, M. R., Viswanath, O., Peck, J., Kaye, A. D., Gill, J. S., & Simopoulos, T. T. (2018) · Pain and Therapy · doi:10.1007/s40122-018-0097-6 · Cited by 405 · cited 1×
“Over the past several decades, the opioid epidemic has evolved from predominantly heroin related misuse to increasing involvement of highly potent synthetic opioids that can be rapidly manufactured and widely distributed [1, 2].”
Self-citationBlanckaert, P., Cannaert, A., Van Uytfanghe, K., Hulpia, F., Deconinck, E., Van Calenbergh, S., & Stove, C. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2738 · Cited by 116 · cited 3×
“2-benzylbenzimidazole opioids were initially studied in the late 1950s as part of pharmaceutical research aimed at developing novel analgesic compounds with high opioid activity [10].”
InfluentialWalton, S. E., Krotulski, A. J., & Logan, B. K. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab117 · Cited by 92 · cited 3×
“The structural differences in these analogs matter clinically because small chemical modifications alter potency, metabolism, and the ability of routine toxicology screenings to detect exposure [14].”
InfluentialKrotulski, A. J., Papsun, D. M., Walton, S. E., & Logan, B. K. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3115 · Cited by 91 · cited 1×
“Metonitazene first appeared in mid-2020 in the recreational drug supply and has been increasing in death investigation casework since its emergence on the market [15].”
Montanari, E., Madeo, G., Pichini, S., Busardò, F. P., & Carlier, J. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000970 · Cited by 89 · cited 3×
“Although several compounds in this class showed their potent opioid effects in early studies, nitazenes were never approved for routine human or veterinary medical use [7].”
InfluentialNitazenes—Heralding a Second Wave for the UK Drug-Related Death Crisis?
Holland, A., Copeland, C. S., Shorter, G. W., Connolly, D. J., Wiseman, A., Mooney, J., Fenton, K., & Harris, M. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00001-x · Cited by 86 · cited 1×
“Detection of nitazene analogs in wastewater samples in multiple countries demonstrate the global distribution of nitazenes [28].”
Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients
Amaducci, A., Aldy, K., Campleman, S. L., Li, S., Meyn, A., Abston, S., Culbreth, R. E., Krotulski, A., Logan, B., Wax, P., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.31264 · Cited by 84 · cited 1×
“Emergency department data suggest that overdoses including new potent opioids can be associated with the greater naloxone requirements than fentanyl overdose, supporting that nitazenes exhibit a very high clinical potency [35].”
Mueller, F., Bogdal, C., Pfeiffer, B., Andrello, L., Ceschi, A., Thomas, A., & Grata, E. (2021) · Forensic Science International · doi:10.1016/j.forsciint.2021.110686 · Cited by 82 · cited 1×
“Its pharmacologic risk is not limited to the parent compound because human metabolism studies have identified various metabolites, including products formed through N-deal-kylation, O-dealkylation, hydroxylation, reduction, and conjugation pathways [22].”
Old Drugs and New Challenges: A Narrative Review of Nitazenes
Pergolizzi Jr, J., Raffa, R., LeQuang, J. A. K., Breve, F., & Varrassi, G. (2023) · Cureus · doi:10.7759/cureus.40736 · Cited by 81
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Saari, T. I., Strang, J., & Dale, O. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01355-6 · Cited by 77
Metadata
- Authors
- Maxwell, M. K., Anwar, A. I., Hasoon, J., & Kaye, A. D.
- Affiliations
- Louisiana State University (US)
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Anwar, Ahmed I.
- Venue
- Current Pain and Headache Reports
- Published
- 2026-07-22
- Volume
- 30
- Issue
- 1
- ISSN
- 1531-3433 (ISSN-L)
- 1534-3081
- PMC
- PMC13391657
- OpenAlex
- W7170076256
- Cited by
- 0
- References
- 48
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Current Pain and Headache Reports (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Keywords
- synthetic opioids, isotonitazene, etonitazene, mu-opioid receptor agonists, opioid overdose, respiratory depression, opioid toxicity, illicit drug markets, counterfeit drugs, toxicity screening, overdose reversal, opioid antagonists
- MeSH terms
- Analgesics, Opioid, Animals, Benzimidazoles, Humans, Opioid-Related Disorders, Illicit Drugs, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs. https://app.cochat.ai/papers/10.1007/s11916-026-01525-0
- The paper
- Maxwell, M. K., Anwar, A. I., Hasoon, J., & Kaye, A. D. (2026). Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs. Current Pain and Headache Reports. https://doi.org/10.1007/s11916-026-01525-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.